Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rubius Therapeutics (RUBY)
OTHER OTC:RUBY
Rubius Therapeutics (RUBY) Stock Price & Analysis
220 Followers
RUBY Stock Chart & Stats
Day’s Range$0.06 - $0.06
52-Week Range― - ―
Previous Close$0.06
Volume755.86K
Average Volume (3M)N/A
Market Cap
$5.15M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Last Dividend Ex-Date
Jan 02, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Rubius Therapeutics News
PremiumPress Releases
Rubius Therapeutics to Provide Strategic UpdateRisk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RUBY FAQ
What was Rubius Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Rubius Therapeutics’s market cap?
Currently, no data Available
When is Rubius Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rubius Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rubius Therapeutics overvalued?
According to Wall Street analysts Rubius Therapeutics’s price is currently Overvalued.
Does Rubius Therapeutics pay dividends?
Rubius Therapeutics pays a Notavailable dividend of $0.06 which represents an annual dividend yield of N/A. See more information on Rubius Therapeutics dividends here
What is Rubius Therapeutics’s EPS estimate?
Rubius Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rubius Therapeutics have?
Currently, no data Available
What happened to Rubius Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rubius Therapeutics?
Among the largest hedge funds holding Rubius Therapeutics’s share is Flagship Pioneering Inc.. It holds Rubius Therapeutics’s shares valued at N/A.
---
Rubius Therapeutics Stock Smart Score
Company Description
Rubius Therapeutics
Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines for cancer, autoimmune diseases, hemophilia, and infectious and metabolic diseases. The company was founded by Avak Kahvejian, Jordi Mata-Fink, and Noubar Afeyan and is headquartered in Cambridge, MA.
---
Technical Analysis
---